Profile

Waldemar Debinski, M.D., Ph.D.Wake Forest School of Medicine

Waldemar Debinski, M.D., Ph.D.

Center of Excellence Director,
Professor,


Contact Information

Academic: 336-713-7634 | Department: 336-716-2011

Email: debinski@wakehealth.edu

Media Medical Expert »

Education & Training

  • M.D., Academy Med Warsaw-Poland, 1981
  • Ph.D., Mcgill University Med-Canada, 1989
Waldemar Debinski, M.D., Ph.D.

Waldemar Debinski, M.D., Ph.D.

Center of Excellence Director, Brain Tumor Center of Excellence
Professor, Cancer Biology
Microbiology & Immunology
Neurosurgery

Research Interests

Brain Neoplasms; Glioblastoma; Ephrin-A1; Receptor, EphA2; Interleukin-13 Receptor alpha2 Subunit
More »

Contact Information

Academic: 336-713-7634 | Department: 336-716-2011

Email: debinski@wakehealth.edu

Media Medical Expert »

Recent Publications

Treatment of brain metastases of lung cancer in the era of precision medicine. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J.. Front Biosci (Elite Ed). 2016;8():219-232.

Pseudo progression identification of glioblastoma with dictionary learning. Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X.. Comput Biol Med. 2016;73():94-101.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.. Future Oncol. 2016;12(17):2009-2020.

Simultaneous targeting of Eph receptors in glioblastoma. Ferluga S, Tome CM, Herpai DM, D'Agostino R, Debinski W.. Oncotarget. 2016;():.

Canine butterfly glioblastomas: a neuroradiological review. Rossmeisl JH, Clapp K, Pancotto TE, Emch S, Robertson JL, Debinski W.. Front Vet Sci. 2016;3():40.

Genomic predictors of imaging response and survival in glioblastoma [abstract]. Soike M, McTyre E, Holmes JA, Paulsson AK, Miller L, Lesser GJ, Strowd RE, Johnson A, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2016;96(2 Suppl):E121-E122.

Mechanisms regulating glioma invasion. Paw I, Carpenter RC [sic] [Carpenter RL], Watabe K, Debinski W, Lo HW.. Cancer Lett. 2015;362(1):1-7.

The gain-of-function truncated GLI1 (TGLI1) promotes glioblastoma angiogenesis by direct upregulation of VEGF-C and TEM7 expression [abstract]. Carpenter RL, Paw I, Sirkisoon S, Xing F, Gibo D, Watabe K, Debinski W, Lo HW.. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia (PA). 2015;():A4165.

Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD.. Oncotarget. 2015;6(22):18945-55.

Neurosurgical techniques for disruption of the blood-brain barrier for glioblastoma treatment. Rodriguez A, Tatter SB, Debinski W.. Pharmaceutics. 2015;7(3):175-187.

The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW.. Oncotarget. 2015;6(26):22653-65.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2015;124(3):447-453.

Frame-based stereotactic biopsy of canine brain masses: technique and clinical results in 26 cases. Rossmeisl JH, Andriani RT, Cecere TE, Lahmers K, LeRoith T, Zimmerman KL, Gibo D, Debinski W.. Front Vet Sci. 2015;2():20.

Invited review-neuroimaging response assessment criteria for brain tumors in veterinary patients. Rossmeisl JH Jr, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S.. Vet Radiol Ultrasound. 2014;55(2):115-132.

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W.. J Neurooncol. 2014;116(3):447-454.

Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD.. Am J Clin Oncol. 2014;37(2):177-181.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2014;119(2):429-435.

Does delay of start of radiation affect clinical outcomes of glioblastoma [abstract]. Randolph DM, Peiffer AM, Paulsson AK, Hinson W, Laxton AW, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S295.

Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? [abstract]. Holmes JA, Paulsson A, Peiffer AM, Miller LD, Xu J, Hinson WH, Lesser GJ, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S291-S292.

Functional presence of M2 macrophage markers in GBM tumor cells [abstract]. Debinski W, Rodriguez A, Gibo D, Tatter SB, Mott R, Lively M, Miller L, Seals DF.. Neuro Oncol. 2014;16(Suppl 3):.

Ephs and ephrins in malignant gliomas. Ferluga S, Debinski W.. Growth Factors. 2014;32(6):190-201.

EphA3 receptor is a molecular target expressed in multiple compartments of GBM [abstract]. Ferluga S, Gibo D, Debinski W.. Neuro Oncol. 2014;16(Suppl 5):v25.

Molecular signature of cancer. Debinski W, Wykosky J, Gibo D, inventors; Wake Forest University Health Sciences, assignee.. United States patent US 8,343,461. 2013 Jan 1. 2013;():.

Multi-level specific targeting of cancer cells. Debinski W, Pandya H, Gibo D, inventors; Wake Forest University Health Sciences, assignee.. United States patent US 8,362,207. 2013 Jan 29. 2013;():.

Biological and structural characterization of glycosylation on Ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W.. J Biol Chem. 2013;288(25):18448-57.

New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM.. PLoS One. 2013;8(10):e77719.

Nucleus-targeted doxorubicin as a potential therapy for glioblastoma [abstract]. Choi YA, Pandya H, Gibo DM, Fokt I, Priebe W, Debinski W.. Neuro Oncol. 2013;15(Suppl 3):40.

Targeting (klaklak)(2), a pro-apoptotic peptide to GMB cells [abstract]. Choi YA, Pandya H, Gibo DM, Debinski W.. Neuro Oncol. 2013;15(Suppl 3):69.

Eph receptor A3 is a molecular therapeutic target for the treatment of glioblastoma [abstract]. Ferluga S, Tome CL, Debinski W.. Neuro Oncol. 2013;15(Suppl 3):43.

Antigens characteristic of M2 type pro-inflammatory macrophages are present on GBM tumor cells [abstract]. Debinski W, Choi YA, Gibo DM.. Neuro Oncol. 2013;15(Suppl 3):63.

Therapeutic efficacy of an optimized quadruply mutated IL13-based bacterial cytotoxin in an orthotopic murine glioma model [abstract]. Nguyen V, Zhu D, Conyers JM, Debinski W, Mintz A.. Cancer Res. 2013;73(8 Suppl 1):A2150.

An interleukin 13 receptor alpha 2-specific peptide homes to human glioblastoma multiforme xenografts. Pandya H, Gibo DM, Garg S, Kridel S, Debinski W.. Neuro Oncol. 2012;14(1):6-18.

Ephs and ephrins in cancer: ephrin-A1 signalling. Beauchamp A, Debinski W.. Semin Cell Dev Biol. 2012;23(1):109-115.

Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. Lema Tome CM, Palma E, Ferlaga S, Lowther WT, Hantgan R, Wykosky J, Debinski W.. J Biol Chem. 2012;287(17):14012-22.

Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas [abstract]. Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA, Gallagher PE.. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 1938.

Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. Pandya H, Debinski W.. BioDrugs. 2012;26(4):235-244.

EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W.. Mol Cell Biol. 2012;32(16):3253-3264.

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13R alpha2 tumor-restricted biomarker. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A.. Neuro Oncol. 2012;14(10):1239-1253.

Epha2/Ephrina1 system in conjunction with TKS5 regulates invadopodia formation in glioblastoma cells [abstract]. Debinski W, Gonzales O, Beauchamp A, Gibo DM, Seals DF.. Neuro Oncol. 2012;14(Suppl 6):14.

Glycosylation is critical for Ephrina1 production and Epha2 activation [abstract]. Ferluga S, Debinski W.. Neuro Oncol. 2012;14(Suppl 6):15.

Highly potent cytotoxin targeting Il-13R alpha 2 in canine and human glioblastoma [abstract]. Gibo DM, Dickinson P, Robertson J, Rossmeisl J, Debinski W.. Neuro Oncol. 2012;14(Suppl 6):31-32.

Interleukin 13 receptor alpha-2 is widely over-expressed in human and canine primary brain tumors as detected by novel bispecies-specific monoclonal antibodies [abstract]. Gibo DM, Debinski W, Bonomo J, Rossmeisl J, Robertson J, Dickinson P.. Neuro Oncol. 2012;14(Suppl 6):47.

The role of proto-oncogenes in tumor-associated macrophage polarization and promotion of GBM tumor progression [abstract]. Seals DF, Burger KL, Gibo DM, Debinski W.. Neuro Oncol. 2012;14(Suppl 6):3.

Molecular and genetic features of highly migratory glioblastoma cells [abstract]. Lema Tome CM, Miller LD, Debinski W.. Neuro Oncol. 2012;14(Suppl 6):162.

Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. Debinski W, Gibo DM.. Cancer Biol Ther. 2011;11(2):254-262.

IL-13R alpha2-targeted therapy escapees: biologic and therapeutic implications. Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A.. Transl Oncol. 2011;4(6):390-400.

Molecular targeting of intracellular compartments specifically in cancer cells. Pandya H, Gibo DM, Debinski W.. Genes Cancer. 2010;1(5):421-433.

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AKMG, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Debinski W, et al.. Proc Natl Acad Sci U S A. 2010;107(46):20021-6.

Convection-enhanced delivery to achieve widespread distribution of viral vectors: predicting clinical implementation. Debinski W, Tatter SB.. Curr Opin Mol Ther. 2010;12(6):647-653.

Elucidation of the release and function of monomeric ephrina1 in glioblastoma multiforme [abstract]. Beauchamp AS, Gibo DM, Wykosky J, Debinski W.. Neuro Oncol. 2010;12(Suppl 4):22.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Cancer Biology

Waldemar Debinski, M.D., Ph.D.

Waldemar Debinski, M.D., Ph.D.

Center of Excellence Director, Brain Tumor Center of Excellence
Professor, Cancer Biology
Microbiology & Immunology
Neurosurgery

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.